Drug Approval | December 28, 2021
India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod
It plans to deliver over 300 million doses to the Indian government
It plans to deliver over 300 million doses to the Indian government
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
The company will market it under the brand name Molflu
The Home Healthcare market is expected to be US $ 14.2 by 2025
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
The approval of shelf life extension is based on the availability of additional stability data, which was submitted to the CDSCO
Subscribe To Our Newsletter & Stay Updated
